Novo Nordisk Rises Again As Amycretin Achieves Rapid Weight Loss
The combination drug hit the 22% weight loss mark in just 36 weeks which has lifted the Danish company’s shares after a recent run of disappointing results.
The combination drug hit the 22% weight loss mark in just 36 weeks which has lifted the Danish company’s shares after a recent run of disappointing results.